Genetic testing for prostate cancer

Genetic testing to determine if you have any mutations associated with an increased risk of prostate cancer.


From 180€ (includes genetic counselling)

Time to result

From 2 weeks, depending on the test

Genetic test for prostate cancer - Know your risk

Risk of prostate cancer in the general population

Approximately one in eight men will develop prostate cancer in his lifetime. In Spain, prostate cancer is the second most frequently diagnosed cancer, behind colorectal cancer and ahead of breast cancer. In men, it is the third most common cause of cancer mortality, behind lung cancer and colorectal cancer.

Between 5% and 10% of prostate cancer cases are thought to be caused mainly by inherited high-risk genetic factors or prostate cancer susceptibility genes. In addition, some of these genetic variants (BRCA2 or HOXB13) are associated with life-threatening forms of prostate cancer.

Thanks to our genetic tests we can determine whether a person has an increased risk of developing this disease and we can also establish whether cases of prostate cancer in a family have a hereditary cause. A genetic test is indicated in the following cases:

  • 3 or more first-degree relatives with prostate cancer.
  • 2 or more first-degree relatives, in the same part of the family, diagnosed with prostate cancer before the age of 55.
  • Prostate cancer in 3 generations on the same side of the family (paternal or maternal).
  • You have or have had prostate cancer before the age of 55.
  • You have prostate cancer and other members of your family have been diagnosed with breast, ovarian or pancreatic cancer.

In the first three cases, genetic testing of your family, preferably of an affected member, can assess your personal risk. In the latter two cases, genetic diagnosis can clarify your risk of a second tumour, as well as the possible risks of other family members.

Genetic testing for prostata cancer

At Genosalut we have more than ten years of experience in carrying out genetic tests for cancer. We attend patients who come directly to our clinic and we also work with a network of specialist doctors who trust us to carry out these tests on their patients.

In the drop-down menu you will find information about the different genetic tests for colorectal cancer that we offer in our laboratory:

Study of a clinically relevant genetic variant associated with hereditary prostate cancer present in other previously diagnosed family members.

Massive sequencing analysis of the following genes associated with increased risk of prostate cancer: AR, BRCA1, BRCA2, CDH1, CHECK2, ELAC2, EPCAM, HOXB13, MLH1, MSH2, MSH6, MSR1, NBN, PTEN, RNASEL, TP53 and ZFHX3.

Thanks to the sequencing of all genes using next generation sequencing (NGS) techniques, we can determine the presence of mutations associated with hereditary prostate cancer.

Thanks to the sequencing of all coding (gene) and non-coding regions using next generation sequencing (NGS) techniques, we can determine the presence of mutations associated with hereditary prostate cancer.

Our value proposal


At Genosalut, we have more than 10 years of experience in counselling people with conditions where a genetic cause has been identified or is thought to be possible.


We are a close laboratory, we respond personally and we take the time to explain the report in detail to doctors and patients.

Professional interpretation of results

Because of our knowledge and experience, we are able to accurately interpret genetic results and offer professional advice.

Reference in the field

We are the point of contact for patients, doctors and clinics in all areas of human genetic diagnostics and prevention.

What are the risk factors for prostate cancer?

  • Age: The risk of prostate cancer increases with age, especially after the age of 50. About 60% of prostate cancers are diagnosed in people aged 65 and older.
  • Race/ethnicity: Men of certain races or ethnicities have a higher risk of prostate cancer. For example, the lifetime risk of prostate cancer is 27% for a black man, 7% for an Asian man and 12% for a white man.
  • Geography: Prostate cancer is most common in North America, northwest Europe, Australia and the Caribbean islands. It is less common in Asia, Africa, Central and South America. Reasons suggested are: increased screening in some developed countries, genetic factors and environmental factors.
  • Family history: Familial prostate cancer accounts for approximately 20% of all prostate cancers. In about half of these cases the underlying cause is a known genetic mutation (hereditary prostate cancer). In the remaining cases it is a combination of as yet unknown mutations and/or shared environmental or lifestyle factors.
  • Other factors: other factors such as diet, obesity and exposure to certain chemicals have been associated with an increased risk of cancer.
Prostate cancer and risk factors
Prevention and peace of mind with the genetic tests of Genosalut

Together with your doctor you can determine strategies for early detection

If you are found to have a known mutation associated with an increased risk of prostate cancer, you can participate in intensive screening programmes for the early detection of these tumours. The earlier a tumour is detected, the better the chances of a cure.

You will know if you can pass on the risk to your offspring

Conversely, if you do not carry the mutation in your family, you know that your risk of prostate cancer is the same as the general population. Your offspring, therefore, will not have an increased risk either.

How can I request a genetic test for prostate cancer?
Request an appointment

Contact us through the form, by e-mail or by telephone to make an appointment with us.

Ask your physician

You can also consult your doctor for information on the possibilities of genetic testing.

We analyse the probe

In our genetic diagnostics laboratory we analyse the sample with the latest technology.

We write a report

We provide a detailed description of the results and, if necessary, genetic counselling.


Prostate cancer begins when cells in the prostate gland start to grow out of control. The prostate is a gland found only in men, just below the bladder and in front of the rectum. Its function is to produce some of the fluid that forms part of semen.

The size of the prostate can change as a man ages. In young men, it is about the size of a walnut, but it can be much larger in older men.

In terms of the incidence of prostate cancer, statistics indicate that 1 in 8 men may develop prostate cancer at some point in their lives. This absolute risk should be taken as a starting point, as individual risk may be higher or lower, depending on uncontrollable factors such as age (most cases are detected in men over 50), race (the risk in men of African descent is higher) and family history. It also depends on controllable factors such as weight and diet.

Prostate cancer is always caused by a genetic abnormality (a “mistake” in the genetic material). Most of the time, 85-90% of the time, these genetic abnormalities occur sporadically, as a result of the natural ageing process. However, the remaining 5-10% are due to a genetic abnormality inherited from the father or mother.

There is no sure way to prevent prostate cancer. Many risk factors, such as age, race and family history, cannot be controlled. But there are some things you can do to reduce your risk of prostate cancer.

Along with a healthy lifestyle (proper weight, balanced diet, and exercise), screening (PSA testing) is an essential tool for the prevention and early detection of prostate cancer. When prostate cancer is detected at an early stage, there is a good chance of recovery.

In the case of a family history, it may also be advisable to perform a genetic test to determine whether there is an increased risk. In case of a positive result, this will help to determine further preventive strategies to be taken.

Approximately 10% of prostate cancers have an inherited cause. Genes associated with hereditary prostate cancer include:

  • BRCA1 and BRCA2: these tumour suppressor genes normally help repair errors in a cell’s DNA (or cause the cell to die if the error cannot be repaired). Inherited mutations in these genes most commonly cause breast and ovarian cancer in women. But changes in these genes (especially BRCA2) are also responsible for prostate cancers.
  • CHEK2, ATM, PALB2 and RAD51D: Mutations in these other DNA repair genes may also be responsible for some hereditary prostate cancers.
  • DNA error repair genes (such as MSH2, MSH6, MLH1 and PMS2): these genes normally help repair DNA errors that can occur during DNA replication. People with inherited mutations in one of these genes may have Lynch syndrome (also known as hereditary non-polyposis colorectal cancer) and have an increased risk of colorectal, prostate and other cancers.
  • RNASEL (formerly HPC1): the normal function of this tumour suppressor gene is to help cells die when something goes wrong inside them. Inherited mutations in this gene can allow abnormal cells to live longer than they should, which can lead to an increased risk of prostate cancer.
  • HOXB13: This gene is important in the development of the prostate gland. Mutations in this gene have been linked to prostate cancer diagnosed at an early age that runs in some families. 

In most cases, the results obtained from the analysis of these genes allow for detailed and informative genetic counselling and a specific recommendation on clinical procedure.

When family history suggests the presence of a heritable mutation, or if a close relative has a mutation in one of the risk genes, predictive genetic testing can be offered.

Genetic testing for prostate cancer is indicated in patients with a family history suggestive of a familial mutation.

Positive result matching the mutation found in the family

If you have tested positive and have been found to have the known familial mutation that is or was responsible for the development of prostate cancer in your family, then you have a significantly higher risk of developing the disease in your lifetime than the rest of the population. It does not imply that you have or will develop the disease, but it does imply that you should intensify surveillance and follow preventive guidelines. In addition, there may be an increased risk of cancer for their offspring.


Positive result in a family in which the causal mutation is not known to exist

In the case of a positive result in a patient for whom no family member with the disease has been or can be tested, it can be assumed that the same mutation also caused the disease in family members who developed prostate cancer. In other words, this person also has a higher risk of developing cancer.


Negative result in a family with known causal mutation

If you have a negative result, this means that the known familial mutation responsible for the development of prostate cancer in the family is not detected in the patient or that there may be a mutation in a gene that has not yet been associated with prostate cancer. This means that you do not have an increased risk of developing prostate cancer. Therefore, you have the same risk as the general population (approximately 4%) of developing prostate cancer in your lifetime.


Negative result in a family with no known causal mutation

If no known mutation has been found in any family member despite there being some people affected by prostate cancer, it may be that another gene is responsible for the development of the cancer and/or that the cancers in your family are not due to an inherited predisposition.

Finally, the result of the genetic test may indicate the presence of a genetic variant that doctors do not have enough information about to be able to assess correctly (variant of uncertain (unknown) significance, VUS). In these situations, the benefit to the patient cannot always be defined.

In order to decide whether a genetic study is advisable, it is ideally important to compile a family tree over 3 generations. By analysing this tree, it can be determined whether there is an increased risk of prostate cancer and a genetic test can be recommended. As a general rule, it is recommended if at least one of the following criteria is met:

  • 3 or more first-degree relatives with prostate cancer.
  • 2 or more first-degree relatives in the same part of the family diagnosed with prostate cancer before the age of 55.
  • Prostate cancer in 3 generations on the same side of the family (paternal or maternal).

If you have or have already had prostate cancer, it is advisable to undergo the study when:

  • You have or have had prostate cancer before the age of 50.
  • Other members of your family have been diagnosed with breast, ovarian or pancreatic cancer.

The decision about whether or not to have a genetic test to establish the risk of prostate cancer is a personal one and should always be made after genetic counselling. This counselling should try to answer any questions about:

  • What it means to do the test
  • How the patient may feel while waiting for the results to come back
  • What kind of actions can be considered after the results have been obtained

Genetic diagnosis is an essential preventive tool. If a mutation in one of the genes is detected through genetic diagnosis, the risk of developing cancer increases considerably. It is therefore vital that people carrying the mutation undergo different preventive diagnostic methods on a regular basis.

Accurate and regular follow-up is essential to reduce the incidence of cancer and radically reduce the associated mortality.

There are private insurance policies that cover preventive genetic analysis in first-degree relatives of affected persons with a detected familial mutation.
However, there are private insurances that do not cover the costs and are therefore paid by the patient.

Request an appointment with us

Opening hours

Monday to Friday from 9.00 am to 1.00 pm

Phone number

+34 616 59 01 65



Camí dels Reis, 308 (Clínica Palma Planas)

Contact form

Reasons for trusting Genosalut

First genetic diagnosis laboratory in the Balearic Islands

Professionals with experience in medical genetics

Detailed report of the results

Personalised attention for each patient

Wide range of genetic tests

Cutting-edge technology